These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Non-NF2 mutations have a key effect on inhibitory immune checkpoints and tumor pathogenesis in skull base meningiomas. Hao S; Huang G; Feng J; Li D; Wang K; Wang L; Wu Z; Wan H; Zhang L; Zhang J J Neurooncol; 2019 Aug; 144(1):11-20. PubMed ID: 31177425 [TBL] [Abstract][Full Text] [Related]
6. Genetic analysis of foramen magnum meningiomas reveals AKT1 mutations uncomplicated by TRAF7 mutations. Hirano Y; Miyawaki S; Sakai Y; Teranishi Y; Okano A; Umekawa M; Hongo H; Torazawa S; Ogawa S; Komura D; Katoh H; Ikemura M; Ushiku T; Ishikawa S; Saito N Acta Neuropathol Commun; 2024 Aug; 12(1):123. PubMed ID: 39103917 [No Abstract] [Full Text] [Related]
7. Genetic characterization and mutational profiling of foramen magnum meningiomas: a multi-institutional study. Hua L; Alkhatib M; Fujio S; Alhasan B; Herold S; Zeugner S; Zolal A; Hijazi MM; Clark VE; Wakimoto H; Shankar GM; Brastianos PK; Barker FG; Cahill DP; Ren L; Eyüpoglu IY; Gong Y; Schackert G; Juratli TA J Neurosurg; 2024 Jul; 141(1):72-78. PubMed ID: 38277657 [TBL] [Abstract][Full Text] [Related]
8. Clinical impact of targeted amplicon sequencing for meningioma as a practical clinical-sequencing system. Yuzawa S; Nishihara H; Yamaguchi S; Mohri H; Wang L; Kimura T; Tsuda M; Tanino M; Kobayashi H; Terasaka S; Houkin K; Sato N; Tanaka S Mod Pathol; 2016 Jul; 29(7):708-16. PubMed ID: 27102344 [TBL] [Abstract][Full Text] [Related]
9. Intraventricular meningiomas frequently harbor NF2 mutations but lack common genetic alterations in TRAF7, AKT1, SMO, KLF4, PIK3CA, and TERT. Jungwirth G; Warta R; Beynon C; Sahm F; von Deimling A; Unterberg A; Herold-Mende C; Jungk C Acta Neuropathol Commun; 2019 Aug; 7(1):140. PubMed ID: 31470906 [TBL] [Abstract][Full Text] [Related]
10. Loss-of-Function Mutations in TRAF7 and KLF4 Cooperatively Activate RAS-Like GTPase Signaling and Promote Meningioma Development. Najm P; Zhao P; Steklov M; Sewduth RN; Baietti MF; Pandolfi S; Criem N; Lechat B; Maia TM; Van Haver D; Corthout N; Eyckerman S; Impens F; Sablina AA Cancer Res; 2021 Aug; 81(16):4218-4229. PubMed ID: 34215617 [TBL] [Abstract][Full Text] [Related]
11. Oncogenic PI3K mutations are as common as AKT1 and SMO mutations in meningioma. Abedalthagafi M; Bi WL; Aizer AA; Merrill PH; Brewster R; Agarwalla PK; Listewnik ML; Dias-Santagata D; Thorner AR; Van Hummelen P; Brastianos PK; Reardon DA; Wen PY; Al-Mefty O; Ramkissoon SH; Folkerth RD; Ligon KL; Ligon AH; Alexander BM; Dunn IF; Beroukhim R; Santagata S Neuro Oncol; 2016 May; 18(5):649-55. PubMed ID: 26826201 [TBL] [Abstract][Full Text] [Related]
12. Identification of novel therapeutic targets through genomic analysis of meningiomas. Komotar RJ; Starke RM; Connolly ES Neurosurgery; 2013 Aug; 73(2):N22-4. PubMed ID: 23867274 [No Abstract] [Full Text] [Related]
13. Genomic analysis of non-neurofibromatosis type 2 meningiomas. Parry PV; Engh JA Neurosurgery; 2013 Jun; 72(6):N18-9. PubMed ID: 23685513 [No Abstract] [Full Text] [Related]
15. Pleiotropic role of TRAF7 in skull-base meningiomas and congenital heart disease. Mishra-Gorur K; Barak T; Kaulen LD; Henegariu O; Jin SC; Aguilera SM; Yalbir E; Goles G; Nishimura S; Miyagishima D; Djenoune L; Altinok S; Rai DK; Viviano S; Prendergast A; Zerillo C; Ozcan K; Baran B; Sencar L; Goc N; Yarman Y; Ercan-Sencicek AG; Bilguvar K; Lifton RP; Moliterno J; Louvi A; Yuan S; Deniz E; Brueckner M; Gunel M Proc Natl Acad Sci U S A; 2023 Apr; 120(16):e2214997120. PubMed ID: 37043537 [TBL] [Abstract][Full Text] [Related]
16. DNA methylation-based classification and grading system for meningioma: a multicentre, retrospective analysis. Sahm F; Schrimpf D; Stichel D; Jones DTW; Hielscher T; Schefzyk S; Okonechnikov K; Koelsche C; Reuss DE; Capper D; Sturm D; Wirsching HG; Berghoff AS; Baumgarten P; Kratz A; Huang K; Wefers AK; Hovestadt V; Sill M; Ellis HP; Kurian KM; Okuducu AF; Jungk C; Drueschler K; Schick M; Bewerunge-Hudler M; Mawrin C; Seiz-Rosenhagen M; Ketter R; Simon M; Westphal M; Lamszus K; Becker A; Koch A; Schittenhelm J; Rushing EJ; Collins VP; Brehmer S; Chavez L; Platten M; Hänggi D; Unterberg A; Paulus W; Wick W; Pfister SM; Mittelbronn M; Preusser M; Herold-Mende C; Weller M; von Deimling A Lancet Oncol; 2017 May; 18(5):682-694. PubMed ID: 28314689 [TBL] [Abstract][Full Text] [Related]
17. Recurrent somatic mutations in POLR2A define a distinct subset of meningiomas. Clark VE; Harmancı AS; Bai H; Youngblood MW; Lee TI; Baranoski JF; Ercan-Sencicek AG; Abraham BJ; Weintraub AS; Hnisz D; Simon M; Krischek B; Erson-Omay EZ; Henegariu O; Carrión-Grant G; Mishra-Gorur K; Durán D; Goldmann JE; Schramm J; Goldbrunner R; Piepmeier JM; Vortmeyer AO; Günel JM; Bilgüvar K; Yasuno K; Young RA; Günel M Nat Genet; 2016 Oct; 48(10):1253-9. PubMed ID: 27548314 [TBL] [Abstract][Full Text] [Related]
18. Diffuse midline skull base meningiomas: identification of a rare and aggressive subgroup of meningiomas. Peyre M; Feuvret L; Sanson M; Navarro S; Boch AL; Loiseau H; Kalamarides M J Neurooncol; 2017 Jul; 133(3):633-639. PubMed ID: 28536991 [TBL] [Abstract][Full Text] [Related]
19. Frequent AKT1E17K mutations in skull base meningiomas are associated with mTOR and ERK1/2 activation and reduced time to tumor recurrence. Yesilöz Ü; Kirches E; Hartmann C; Scholz J; Kropf S; Sahm F; Nakamura M; Mawrin C Neuro Oncol; 2017 Aug; 19(8):1088-1096. PubMed ID: 28482067 [TBL] [Abstract][Full Text] [Related]
20. The spatial phenotype of genotypically distinct meningiomas demonstrate potential implications of the embryology of the meninges. Fountain DM; Smith MJ; O'Leary C; Pathmanaban ON; Roncaroli F; Bobola N; King AT; Evans DG Oncogene; 2021 Feb; 40(5):875-884. PubMed ID: 33262459 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]